IN THE CLAIMS

Please amend the claims as follows.

Claims 1-34 (Canceled)

35. (New) A method of diagnosing a cancer in a subject, comprising:

a) measuring a level of expression of an erbB-3 gene in a sample from the subject; and

b) comparing the level of expression of the erbB-3 gene in the sample from the subject to a level of expression of the erbB-3 gene in a sample from a control subject, whereby an increase in the level of expression of the erbB-3 gene in the sample from the subject, relative to the level of expression of the erbB-3 gene in the sample from the control subject, indicates a diagnosis of cancer in the subject.

36. (New) The method of claim 35, wherein the subject is a human subject.

37. (New) The method of claim 35, wherein the sample is a tumor sample.

38. (New) The method of claim 35, wherein the cancer is a breast cancer.

39. (New) The method of claim 35, wherein measuring the level of expression of an erbB-3 gene comprises:

a) hybridizing nucleic acid in the sample from the subject with a probe that specifically hybridizes with erbB-3 nucleic acid; and

b) comparing the amount of hybridization in the sample from the subject to the amount of hybridization in the sample from the control subject, whereby an increased amount of hybridization in the sample from the subject, relative to the amount of hybridization in the sample from the control subject, indicates a diagnosis of cancer in the subject.

40. (New) The method of claim 39, wherein the erbB-3 nucleic acid is genomic DNA.

41. (New) The method of claim 39, wherein the erbB-3 nucleic acid is RNA.

42. (New) The method of claim 39, wherein the erbB-3 nucleic acid is cDNA.

43. (New) A method of classifying a cancer as being correlated with increased expression of an erbB-3 gene, comprising:

a) measuring the level of expression of the erbB-3 gene in a sample from a subject diagnosed with cancer; and

b) comparing the level of expression of the erbB-3 gene in the sample from the subject to the level of expression of the erbB-3 gene in a sample from a control subject, whereby an increase in the level of expression of the erbB-3 gene in the sample from the subject, relative to the level of expression of the erbB-3 gene in the sample from the control subject, classifies the cancer as being correlated with increased expression of the erbB-3 gene.

44. (New) The method of claim 43, wherein the subject is a human subject.

45. (New) The method of claim 43, wherein the sample is a tumor sample.

46. (New) The method of claim 43, wherein the cancer is breast cancer.

47. (New) The method of claim 43, wherein the measurement of expression of the erbB-3 gene comprises:

a) hybridizing nucleic acid in the sample from the subject with a probe that specifically hybridizes with erbB-3 nucleic acid; and

b) comparing the amount of hybridization in the sample from the subject to the amount of hybridization in the sample from the control subject, whereby an increased amount of

hybridization in the sample from the subject, relative to the amount of hybridization in the sample from the control subject, classifies the cancer as being correlated with increased expression of the erbB-3 gene

48. (New) The method of claim 47, wherein the erbB-3 nucleic acid is genomic DNA.

49. (New) The method of claim 47, wherein the erbB-3 nucleic acid is mRNA.

50. (New) The method of claim 47, wherein the erbB-3 nucleic acid is cDNA.